LMK-235

• CAT Number: I001606
• CAS Number: 1418033-25-6
• Molecular Formula: C15H22N2O4
• Molecular Weight: 294.4
• Purity: ≥95%
• Target: HDAC
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: 0.49 μM (A2780) and 0.32 μM (A2780 CisR) [1]
• InChIKey: VRYZCEONIWEUAV-UHFFFAOYSA-N

LMK235 is a HDAC inhibitor, previously shown to be a novel and specific inhibitor of human HDAC4 and 5, with IC50 values of 0.49 μM (A2780) and 0.32 μM (A2780 CisR).IC50 value: 0.49 μM (A2780) and 0.32 μM (A2780 CisR) [1]Target: HDAC4/ HDAC5In vitro: In the cisplatin-resistant HNSCC cell lines Cal27 CisR and Kyse510, LMK-235 enhanced markedly the cytotoxicity of cisplatin [1]. A comparison of the IC50 values of the four most potent compounds with those obtained for HepG2 cells (Table 2) indicates that LMK-235 is cytotoxic [2].In vivo:

Reference

[1]. Linda Marek, et al. Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. J. Med. Chem., 2013, 56 (2), pp 427–436
[2]. Finn K. Hansena, et al. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. European Journal of Medicinal Chemistry, Volume 82, 23 July 2014, Pages 204–213.